{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:34:14Z","timestamp":1783726454755,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jvacx.2024.100525","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T05:36:14Z","timestamp":1720935374000},"page":"100525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["HTLV-1 vaccination Landscape: Current developments and challenges"],"prefix":"10.1016","volume":"19","author":[{"given":"Arash","family":"Letafati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Bahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Salahi Ardekani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Nayerain Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar","family":"Nikzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"norouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Aboofazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-2252","authenticated-orcid":false,"given":"Sayed-Hamidreza","family":"Mozhgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100525_b0005","doi-asserted-by":"crossref","unstructured":"Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. F1000Research. 2019;8.","DOI":"10.12688\/f1000research.17479.1"},{"key":"10.1016\/j.jvacx.2024.100525_b0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100525_b0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/aid.2021.0230","article-title":"Human T cell lymphotropic virus type 1 global prevalence associated with the human development index: systematic review with meta-analysis","volume":"39","author":"Sampaio","year":"2023","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0020","doi-asserted-by":"crossref","first-page":"e00078","DOI":"10.1128\/cmr.00078-21","article-title":"Clinical and public health implications of human T-lymphotropic virus type 1 infection","volume":"35","author":"Legrand","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-020-0512-z","article-title":"The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil","volume":"17","author":"Ishak","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.jvacx.2024.100525_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2016.10.015","article-title":"Reducing the global burden of HTLV-1 infection: an agenda for research and action","volume":"137","author":"Willems","year":"2017","journal-title":"Antiviral Res"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100525_b0035","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-13-3169","article-title":"CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I\u2013infected cells in adult T-cell Leukemia\/Lymphoma","volume":"20","author":"Kobayashi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s42003-022-03467-w","article-title":"RAISING is a high-performance method for identifying random transgene integration sites","volume":"5","author":"Wada","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.jvacx.2024.100525_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1073779","article-title":"Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years","volume":"14","author":"Santana","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-023-08289-7","article-title":"Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies","volume":"23","author":"Seighali","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100525_b0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/aid.1996.12.403","article-title":"Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects","volume":"12","author":"Bomford","year":"1996","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jvacx.2024.100525_b0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fmicb.2012.00222","article-title":"Cellular factors involved in HTLV-1 entry and pathogenicit","volume":"3","author":"Hoshino","year":"2012","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"npj Vaccines"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100525_b0070","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/j.1460-2075.1987.tb02660.x","article-title":"Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection","volume":"6","author":"Shida","year":"1987","journal-title":"Embo j"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0075","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0042-6822(92)90208-7","article-title":"Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: induction of neutralizing antibody","volume":"191","author":"Ford","year":"1992","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/aid.1995.11.307","article-title":"Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits","volume":"11","author":"Franchini","year":"1995","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Pt 1","key":"10.1016\/j.jvacx.2024.100525_b0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1099\/0022-1317-78-1-147","article-title":"Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene","volume":"78","author":"Ibuki","year":"1997","journal-title":"J Gen Virol"},{"issue":"13","key":"10.1016\/j.jvacx.2024.100525_b0090","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/JVI.75.13.5939-5948.2001","article-title":"Immunogenicity and protective efficacy of recombinant human T-cell leukemia\/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)","volume":"75","author":"Kazanji","year":"2001","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100525_b0095","first-page":"1095","article-title":"Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood","volume":"126","author":"Sugata","year":"2015","journal-title":"J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12985-023-02264-z","article-title":"Preclinical assessment of an anti-HTLV-1 heterologous DNA\/MVA vaccine protocol expressing a multiepitope HBZ protein","volume":"20","author":"Daian e Silva","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.jvacx.2024.100525_b0105","doi-asserted-by":"crossref","unstructured":"Liu L, Morrow MP, Bagarazzi M. Clinical Use of DNA Vaccines. Handbook of Electroporation. 2017;25:1933-52.","DOI":"10.1007\/978-3-319-32886-7_106"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100525_b0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1189\/jlb.68.6.793","article-title":"DNA vaccination: antigen presentation and the induction of immunity","volume":"68","author":"Devon","year":"2000","journal-title":"Leukocyte Biol"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100525_b0115","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/dna.1997.16.1439","article-title":"Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic and protein immunizations in mice","volume":"16","author":"Grange","year":"1997","journal-title":"DNA Cell Biol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<300::AID-IJC27>3.0.CO;2-J","article-title":"Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene","volume":"71","author":"Kazanji","year":"1997","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.jvacx.2024.100525_b0125","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1128\/JVI.74.20.9610-9616.2000","article-title":"Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine","volume":"74","author":"Ohashi","year":"2000","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100525_b0130","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0264-410X(99)00565-4","article-title":"Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice","volume":"18","author":"Armand","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100525_b0135","doi-asserted-by":"crossref","unstructured":"Lidder P, Sonnino A. Chapter 1 - Biotechnologies for the Management of Genetic Resources for Food and Agriculture. In: Goodwin SF, Friedmann T, Dunlap JC, editors. Advances in Genetics. 78: Academic Press; 2012. p. 1-167.","DOI":"10.1016\/B978-0-12-394394-1.00001-8"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100525_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2051013613494535","article-title":"Novel HIV vaccine strategies: overview and perspective","volume":"1","author":"Cohen","year":"2013","journal-title":"Ther Adv Vaccines"},{"issue":"17 Suppl","key":"10.1016\/j.jvacx.2024.100525_b0145","first-page":"5687s","article-title":"Subunit vaccine protects Macaca nemestrina (pig-tailed macaque) against simian T-cell lymphotropic virus type I challenge","volume":"50","author":"Dezzutti","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.jvacx.2024.100525_b0150","doi-asserted-by":"crossref","unstructured":"Marintcheva B. Chapter 8 - Viruses as Tools for Vaccine Development. In: Marintcheva B, editor. Harnessing the Power of Viruses: Academic Press; 2018. p. 217-42.","DOI":"10.1016\/B978-0-12-810514-6.00008-8"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3835(92)90274-Y","article-title":"Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46","volume":"66","author":"Lairmore","year":"1992","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100525_b0160","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1128\/jvi.68.10.6323-6331.1994","article-title":"Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization","volume":"68","author":"Tanaka","year":"1994","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0165","first-page":"83","article-title":"Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I)","volume":"1","author":"Conrad","year":"1995","journal-title":"Biomed Pept Proteins Nucleic Acids"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4049\/jimmunol.154.1.399","article-title":"A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies","volume":"154","author":"Baba","year":"1995","journal-title":"J Immunol"},{"issue":"9\u201310","key":"10.1016\/j.jvacx.2024.100525_b0175","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0264-410X(00)00340-6","article-title":"Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide","volume":"19","author":"Frangione-Beebe","year":"2000","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.jvacx.2024.100525_b0180","doi-asserted-by":"crossref","first-page":"24141","DOI":"10.1074\/jbc.M313210200","article-title":"De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies","volume":"279","author":"Sundaram","year":"2004","journal-title":"J Biol Chem"},{"issue":"21\u201322","key":"10.1016\/j.jvacx.2024.100525_b0185","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/S0264-410X(03)00179-8","article-title":"A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design","volume":"21","author":"Sundaram","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0190","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-3011.2003.00113.x","article-title":"Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1","volume":"63","author":"Sundaram","year":"2004","journal-title":"J Pept Res"},{"issue":"2\u20133","key":"10.1016\/j.jvacx.2024.100525_b0195","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molimm.2009.09.006","article-title":"Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia","volume":"47","author":"Kozako","year":"2009","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100525_b0200","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1742-4658.2011.08055.x","article-title":"Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant","volume":"278","author":"Kozako","year":"2011","journal-title":"Febs J"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100525_b0205","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00262-012-1284-7","article-title":"A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope","volume":"61","author":"Kobayashi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jvacx.2024.100525_b0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micpath.2016.05.012","article-title":"Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46","volume":"97","author":"Amirnasr","year":"2016","journal-title":"Microb Pathog"},{"issue":"1\u20132","key":"10.1016\/j.jvacx.2024.100525_b0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijpharm.2018.07.069","article-title":"The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1","volume":"549","author":"Kabiri","year":"2018","journal-title":"Int J Pharm"},{"issue":"33","key":"10.1016\/j.jvacx.2024.100525_b0220","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2018.07.002","article-title":"In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection","volume":"36","author":"Mulherkar","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100525_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120920","article-title":"Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein ((t)Tax-(t)Env:mFc\u03b32a) for HTLV-1 vaccine development","volume":"308","author":"Shafifar","year":"2022","journal-title":"Life Sci"},{"issue":"Pt 2","key":"10.1016\/j.jvacx.2024.100525_b0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1099\/0022-1317-74-2-211","article-title":"Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system","volume":"74","author":"Arp","year":"1993","journal-title":"J Gen Virol"},{"issue":"Pt 5","key":"10.1016\/j.jvacx.2024.100525_b0235","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1099\/vir.0.81582-0","article-title":"Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus)","volume":"87","author":"Kazanji","year":"2006","journal-title":"J Gen Virol"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100525_b0240","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-06-0384","article-title":"In vitro Peptide Immunization of Target Tax Protein Human T-Cell Leukemia Virus Type 1\u2013Specific CD4+ Helper T Lymphocytes","volume":"12","author":"Kobayashi","year":"2006","journal-title":"Clinical cancer research."},{"key":"10.1016\/j.jvacx.2024.100525_b0245","first-page":"12","article-title":"Tax peptide vaccine suppressed the leukemia in humanized mouse model of ATL","author":"Fujisawa caS-iL","year":"2015","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0255","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100525_b0260","article-title":"DC-Based Vaccines for Cancer Immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"26","key":"10.1016\/j.jvacx.2024.100525_b0265","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.vaccine.2014.03.087","article-title":"In vivo immunogenicity of Tax(11\u201319) epitope in HLA-A2\/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine","volume":"32","author":"Sagar","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100525_b0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100525_b0275","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4049\/jimmunol.1601557","article-title":"HTLV-1 Tax-Specific CTL Epitope-Pulsed Dendritic Cell Therapy Reduces Proviral Load in Infected Rats with Immune Tolerance against Tax","volume":"198","author":"Ando","year":"2017","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100525_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/v13081461","article-title":"An epitope platform for safe and effective HTLV-1-immunization: potential applications for mRNA and peptide-based vaccines","volume":"13","author":"Lucchese","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100525_b0285","doi-asserted-by":"crossref","first-page":"e0162323","DOI":"10.1128\/jvi.01623-23","article-title":"An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits","volume":"98","author":"Tu","year":"2024","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0290","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.1100070","article-title":"Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process","volume":"187","author":"Kuo","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100525_b0295","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cas.14800","article-title":"Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients","volume":"112","author":"Ishizawa","year":"2021","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100525_b0300","doi-asserted-by":"crossref","DOI":"10.1515\/jib-2018-0051","article-title":"Predicting and designing epitope ensemble vaccines against HTLV-1","volume":"16","author":"Alam","year":"2020","journal-title":"J Integr Bioinform"},{"key":"10.1016\/j.jvacx.2024.100525_b0305","article-title":"Designing a novel multi-epitope vaccine against Htlv-1 related adult T-cell leukemia\/lymphoma: an in silico approach","volume":"17","author":"Farahi","year":"2020","journal-title":"Curr Proteomics"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100525_b0310","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1080\/07391102.2021.1889669","article-title":"In silico identification of epitope-based vaccine candidates against HTLV-1","volume":"40","author":"Jahantigh","year":"2022","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100525_b0315","doi-asserted-by":"crossref","first-page":"e0248001","DOI":"10.1371\/journal.pone.0248001","article-title":"Epitope-based universal vaccine for Human T-lymphotropic virus-1 (HTLV-1)","volume":"16","author":"Raza","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100525_b0320","doi-asserted-by":"crossref","first-page":"e0258443","DOI":"10.1371\/journal.pone.0258443","article-title":"Rational design of chimeric Multiepitope Based Vaccine (MEBV) against human T-cell lymphotropic virus type 1: An integrated vaccine informatics and molecular docking based approach","volume":"16","author":"Tariq","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100525_b0325","article-title":"An insight overview on COVID-19 mRNA vaccines: advantageous, pharmacology, mechanism of action, and prospective considerations","volume":"109934","author":"Mirtaleb","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100525_b0335","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"Pt 12","key":"10.1016\/j.jvacx.2024.100525_b0340","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1099\/vir.0.19334-0","article-title":"The immune control and cell-to-cell spread of human T-lymphotropic virus type 1","volume":"84","author":"Bangham","year":"2003","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100525_b0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/v8030074","article-title":"Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission","volume":"8","author":"Gross","year":"2016","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100525_b0350","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1128\/JVI.02358-14","article-title":"Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography","volume":"89","author":"Cao","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100525_b0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12879-023-08289-7","article-title":"Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies","volume":"23","author":"Seighali","year":"2023","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T03:46:42Z","timestamp":1723520802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":71,"alternative-id":["S2590136224000986"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100525","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HTLV-1 vaccination Landscape: Current developments and challenges","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100525"}}